US equities |
AAPL $328.69 ▼-2.85% MU $859.36 ▲+3.09% NVDA $207.69 ▲+2.79% AMD $491.38 ▲+5.26% PLTR $174.40 ▼-2.21% SNDK $1,131.55 ▲+5.25% ORCL $125.82 ▲+5.54% SPCX $141.65 ▲+3.87%
FinancialContent

Lisata Therapeutics, Inc. - Common Stock (NQ:LSTA)

1.030 +0.020 (+1.98%)
Delayed Quote Updated: 10:49 AM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lisata Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
Veteran biopharma CFO brings more than 15 years of public-company financial leadership across development, approval and commercial launch; joins Audit Committee 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Late-breaking presentation will highlight Phase 2b clinical data for MAR001, a potential first-in-class antibody targeting ANGPTL4 designed to lower triglycerides and improve metabolic function 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Lisata Therapeutics Provides Update Following Termination of Merger Agreement
From Lisata Therapeutics, Inc.
Via GlobeNewswire
These stocks are moving in today's after hours session ↗
Via Chartmill
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Tuesday's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics... 
Via Benzinga
News headline image
Lisata Therapeutics Announces Commencement of Tender Offer by Kuva Labs Inc.
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq –
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether NSA, LSTA, TALK are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SILA, LSTA, ESPR are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq -
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SILA and LSTA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether TALK, UBFO, LSTA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Lisata Therapeutics Enters into Definitive Agreement to be Acquired by Kuva Labs, Inc.
From Lisata Therapeutics, Inc.
Via GlobeNewswire
News headline image
Halper Sadeh LLC Reminds Shareholders of SKYT, NATH, SNCY, LSTA of the Firm’s Investigations
Shareholders should contact the firm as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SkyWater Technology, Inc. (Nasdaq - SKYT), Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages NATH, PEN, RAPT, LSTA Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights 
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC Encourages SKYT, NATH, LSTA Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Lisata Therapeutics Announces Mutual Termination of License Agreement with Qilu Pharmaceutical for Certepetide
Lisata regains full development rights to certepetide in the Greater China Region 
From Lisata Therapeutics, Inc.
Via GlobeNewswire
The trading volume of these stocks is deviating from the norm in today's session. ↗
Via Chartmill
News headline image
LSTA Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Lisata Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Lisata Shares Nearly Double On Buyout Offer: Here Are The Details ↗
Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement. 
Via Stocktwits
Topics Workforce
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nathan’s Famous, Inc. (Nasdaq – NATH), Lisata Therapeutics, Inc. (Nasdaq – LSTA), Sun Country Airlines Holdings, Inc. (Nasdaq - SNCY), Ventyx Biosciences, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >